Founded with the mission to accelerate medical discoveries, LumaCyte provides innovative diagnostic tools for researchers. Their core technology, Laser Force Cytology™, offers real-time, label-free bioprocess analytics and production monitoring, enabling the detection of subtle phenotypic changes in cells without the need for antibody or genetic labeling. The flagship product, Radiance®, is a single-cell analysis platform that delivers advanced analytics for bioprocess monitoring and quality control, targeting the biomedical research and pharmaceutical markets.
LumaCyte's groundbreaking approach has attracted notable investors and industry leaders who recognize the potential of unbiased cell analysis. The company has achieved significant milestones in advancing cell analysis technology, contributing to more efficient and accurate medical research. By eliminating the biases associated with traditional antibody-based diagnostics, LumaCyte has made a substantial impact on the field, empowering researchers to make faster and more informed discoveries.
